Trial of the Week: CHAMPION PHOENIX
Jack Pluenneke joins to discuss a March 2024 Trial of the Week, “Effect of platelet inhibition with cangrelor during PCI on ischemic events” the CHAMPION PHOENIX trial, published in 2013 in NEJM.
Pharmacy to Dose: The Critical Care Podcast
Audio is streamed directly from the publisher (traffic.megaphone.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Trial of the Week: CHAMPION PHOENIX
Special Guest: Jack Pluenneke, PharmD, BCCP @JackPluenneke
Jack Pluenneke joins to discuss a March 2024 Trial of the Week, “Effect of platelet inhibition with cangrelor during PCI on ischemic events” the CHAMPION PHOENIX trial, published in 2013 in NEJM.
We review PK/PD advantages with cangrelor, go over the CHAMPION trials, and then highlight why the CHAMPION PHOENIX trial was necessary. Then we dive into the Trial of the Week: CHAMPION PHOENIX trial and discuss its findings as well as study design. Are these patients we’d see in our ICU? How does cangrelor compare to glycoprotein 2b/3a inhibitors? Is it a weakness that the comparator group uses clopidogrel? The episode closes with medication safety considerations, cangrelor’s place in therapy, and much more.
Reference list: https://pharmacytodose.files.wordpress.com/2024/03/champion-phoenix-trial-of-the-week-references-1.pdf
PharmacyToDose.Com
@PharmacyToDose
Learn more about your ad choices. Visit megaphone.fm/adchoices